Ikena Oncology (IKNA) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 16, 2026, and will be held virtually, allowing shareholders to vote and ask questions online.

• Shareholders of record as of April 28, 2026, are eligible to vote on three key proposals: election of two Class II directors, ratification of the independent auditor, and approval of amendments to the 2025 Equity Incentive Plan.

• The company completed a merger in July 2025, resulting in a new corporate structure and a reverse stock split.

Voting matters and shareholder proposals

• Proposal 1: Elect two nominees for Class II directors to serve until the 2029 annual meeting.

• Proposal 2: Ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026.

• Proposal 3: Approve amendments to the 2025 Equity Incentive Plan, increasing authorized shares by 850,000 and modifying the annual share reserve calculation.

• Shareholders may submit proposals for the 2027 annual meeting by December 31, 2026, for inclusion in the proxy statement.

Board of directors and corporate governance

• The board is divided into three classes, with staggered three-year terms; six directors currently serve.

• Board leadership is separated between a non-executive chair and a lead independent director.

• All board committees (Audit, Compensation, Nominating and Corporate Governance) are composed of independent directors.

• The board emphasizes diversity, independence, and relevant expertise in director nominations.